Topical treatment with CYP26 inhibitor talarozole (R115866) dose dependently alters the expression of retinoid-regulated genes in normal human epidermis

British Journal of Dermatology

Volumn 160, Issue 1, 2009, Pages 26-36

  Pavez Lorie E ^a   Cools, M ^b   Borgers, M ^b,c   Wouters, L ^d   Shroot, B ^e   Hagforsen, E ^a   Torma H ^a   Vahlquist, A ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b Research and Development   (Belgium)

^c Barrier Therapeutics Nv   (Belgium)

^d MAASTRICHT UNIVERSITY   (Netherlands)

^e Barrier Therapeutics   (United States)

Author keywords

All trans retinoic acid; CYP26 protein; Cytokeratin; Metabolism; Skin

Indexed keywords

CYTOCHROME P450 26A1; CYTOKERATIN; ENZYME INHIBITOR; INTERLEUKIN 1ALPHA; N [4 [2 ETHYL 1 (1H 1,2,4 TRIAZOL 1 YL)BUTYL]PHENYL] 2 BENZOTHIAZOLAMINE; PROTEIN KRT2; PROTEIN KRT4; RETINAL DEHYDROGENASE; RETINOIC ACID BINDING PROTEIN; RETINOL ACYLTRANSFERASE; TALAROZOLE; TRIAZOLE DERIVATIVE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BLOOD TOXICITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; EPIDERMIS; ERYTHEMA; FEMALE; GENE EXPRESSION; HUMAN; HUMAN EXPERIMENT; HUMAN TISSUE; IMMUNOFLUORESCENCE; MALE; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PRURITUS; PUNCH BIOPSY; RANDOMIZED CONTROLLED TRIAL; REAL TIME POLYMERASE CHAIN REACTION; SKIN BIOPSY; SKIN INFLAMMATION; SKIN IRRITATION;

ADMINISTRATION, TOPICAL; ADOLESCENT; ADULT; ANALYSIS OF VARIANCE; BENZOTHIAZOLES; BIOLOGICAL MARKERS; CELL PROLIFERATION; CYTOCHROME P-450 ENZYME SYSTEM; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; EPIDERMIS; FEMALE; GENE EXPRESSION; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; RECEPTORS, RETINOIC ACID; RETINAL DEHYDROGENASE; RETINOIDS; RNA, MESSENGER; TRIAZOLES; YOUNG ADULT;

EID: 57649197948     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2008.08895.x     Document Type: Article

References (46)

1. van de Kerkhof PC. Update on retinoid therapy of psoriasis in: an update on the use of retinoids in dermatology. Dermatol Ther 2006 19 : 252 63.
2. DiGiovanna JJ. Retinoid treatment of the disorders of cornification. In : Retinoids and Carotenoids in Dermatology (Vahlquist A, Duvic M, eds Vol. 39. New York : Informa Healthcare USA Inc., 2007 153 69.
3. Taylor G, Shalita A. Retinoid therapy of acne and sebocyte-related disorders. In : Retinoids and Carotenoids in Dermatology (Vahlquist A, Duvic M, eds Vol. 39. New York : Informa Healthcare USA Inc., 2007 103 23.
4. Mills CM, Marks R. Adverse reactions to oral retinoids. An update. Drug Saf 1993 9 : 280 90.
5. Vahlquist A. Retinoids and the skin: from vitamin A in human epidermis to the pharmacology of oral retinoids in dermatology In : Retinoids and Carotenoids in Dermatology (Vahlquist A, Duvic M, eds Vol. 39. New York : Informa Healthcare USA Inc., 2007 55 68.
6. Roos TC, Jugert FK, Merk HF et al. Retinoid metabolism in the skin. Pharmacol Rev 1998 50 : 315 33.
7. Noy N. Retinoid-binding proteins: mediators of retinoid action. Biochem J 2000 348 : 481 95.
8. Napoli JL. Interactions of retinoid binding proteins and enzymes in retinoid metabolism. Biochim Biophys Acta 1999 1440 : 139 62.
9. Elder JT, Cromie MA, Griffiths CE et al. Stimulus-selective induction of CRABP-II mRNA: a marker for retinoic acid action in human skin. J Invest Dermatol 1993 100 : 356 9.
10. Virtanen M, Törmä H, Vahlquist A. Keratin 4 upregulation by retinoic acid in vivo: a sensitive marker for retinoid bioactivity in human epidermis. J Invest Dermatol 2000 114 : 487 93.
11. Saurat JH, Didierjean L, Masgrau E et al. Topical retinaldehyde on human skin: biologic effects and tolerance. J Invest Dermatol 1994 103 : 770 4.
12. Abu-Abed SS, Beckett BR, Chiba H et al. Mouse P450RAI (CYP26) expression and retinoic acid-inducible retinoic acid metabolism in F9 cells are regulated by retinoic acid receptor gamma and retinoid X receptor alpha. J Biol Chem 1998 273 : 2409 15.
13. Sonneveld E, van den Brink CE, van der Leede BM et al. Human retinoic acid (RA) 4-hydroxylase (CYP26) is highly specific for all-trans-RA and can be induced through RA receptors in human breast and colon carcinoma cells. Cell Growth Differ 1998 9 : 629 37.
14. Ray WJ, Bain G, Yao M et al. CYP26, a novel mammalian cytochrome P450, is induced by retinoic acid and defines a new family. J Biol Chem 1997 272 : 18702 8.
15. Taimi M, Helvig C, Wisniewski J et al. A novel human cytochrome P450, CYP26C1, involved in metabolism of 9-cis and all-trans isomers of retinoic acid. J Biol Chem 2004 279 : 77 85.
16. Duell EA, Åström A, Griffiths CE et al. Human skin levels of retinoic acid and cytochrome P-450-derived 4-hydroxyretinoic acid after topical application of retinoic acid in vivo compared to concentrations required to stimulate retinoic acid receptor-mediated transcription in vitro. J Clin Invest 1992 90 : 1269 74.
17. Smith G, Wolf CR, Deeni YY et al. Cutaneous expression of cytochrome P450 CYP2S1: individuality in regulation by therapeutic agents for psoriasis and other skin diseases. Lancet 2003 361 : 1336 43.
18. Loudig O, Babichuk C, White J et al. Cytochrome P450RAI(CYP26) promoter: a distinct composite retinoic acid response element underlies the complex regulation of retinoic acid metabolism. Mol Endocrinol 2000 14 : 1483 97.
19. van Pelt JP, de Jong EM, de Bakker ES et al. Effects of systemic treatment with liarozole on cutaneous inflammation, epidermal proliferation and differentiation in extensive plaque psoriasis. Skin Pharmacol Appl Skin Physiol 1998 11 : 70 9.
20. Lucker GP, Verfaille CJ, Heremans AM et al. Topical liarozole in ichthyosis: a double-blind, left-right comparative study followed by a long-term open maintenance study. Br J Dermatol 2005 152 : 566 9.
21. Lucker GP, Heremans AM, Boegheim PJ et al. Oral treatment of ichthyosis by the cytochrome P-450 inhibitor liarozole. Br J Dermatol 1997 136 : 71 5.
22. Verfaille CJ, Vanhoutte FP, Blanchet-Bardon C et al. Oral liarozole vs. acitretin in the treatment of ichthyosis: a phase II/III multicentre, double-blind, randomized, active-controlled study. Br J Dermatol 2007 156 : 965 73.
23. Kang S, Duell EA, Kim KJ et al. Liarozole inhibits human epidermal retinoic acid 4-hydroxylase activity and differentially augments human skin responses to retinoic acid and retinol in vivo. J Invest Dermatol 1996 107 : 183 7.
24. Njar VC, Gediya L, Purushottamachar P et al. Retinoic acid metabolism blocking agents (RAMBAs) for treatment of cancer and dermatological diseases. Bioorg Med Chem 2006 14 : 4323 40.
25. Vanden Bossche H, Koymans L, Moereels H. P450 inhibitors of use in medical treatment: focus on mechanisms of action. Pharmacol Ther 1995 67 : 79 100.
26. Bovenschen HJ, Otero ME, Langewouters AM et al. Oral retinoic acid metabolism blocking agent Rambazole for plaque psoriasis: an immunohistochemical study. Br J Dermatol 2007 156 : 263 70.
27. Verfaille C, Thissen C, Bovenschen H et al. Oral R115866 in the treatment of moderate to severe plaque-type psoriasis. J Eur Acad Dermatol Venereol 2007 21 : 1038 46.
28. Verfaille CJ, Coel M, Boersma IH et al. Oral R115866 in the treatment of moderate to severe facial acne vulgaris: an exploratory study. Br J Dermatol 2007 157 : 122 6.
29. Stoppie P, Borgers M, Borghgraef P et al. R115866 inhibits all-trans-retinoic acid metabolism and exerts retinoidal effects in rodents. J Pharmacol Exp Ther 2000 293 : 304 12.
30. Vahlquist A. Vitamin A in human skin: I. detection and identification of retinoids in normal epidermis. J Invest Dermatol 1982 79 : 89 93.
31. Törmä H, Geijer S, Gester T et al. Variations in the mRNA expression of inflammatory mediators, markers of differentiation and lipid-metabolizing enzymes caused by sodium lauryl sulphate in cultured human keratinocytes. Toxicol In Vitro 2006 20 : 472 9.
32. Vandesompele J, De Preter K, Pattyn F et al. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol 2002 3 : RESEARCH0034.
33. Verbeke G, Molenberghs G. Linear Mixed Models in Practice: a SAS-Oriented Approach. New York, NY : Springer, 1997.
34. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc Ser B 1995 57 : 289 300.
35. White JA, Guo YD, Baetz K et al. Identification of the retinoic acid-inducible all-trans-retinoic acid 4-hydroxylase. J Biol Chem 1996 271 : 29922 7.
36. Loudig O, Maclean GA, Dore NL et al. Transcriptional co-operativity between distant retinoic acid response elements in regulation of Cyp26A1 inducibility. Biochem J 2005 392 : 241 8.
37. Kang S, Duell EA, Fisher GJ et al. Application of retinol to human skin in vivo induces epidermal hyperplasia and cellular retinoid binding proteins characteristic of retinoic acid but without measurable retinoic acid levels or irritation. J Invest Dermatol 1995 105 : 549 56.
38. Steijlen PM, Reifenschweiler DO, Ramaekers FC et al. Topical treatment of ichthyoses and Darier's disease with 13-cis-retinoic acid. A clinical and immunohistochemical study. Arch Dermatol Res 1993 285 : 221 6.
39. White JA, Beckett-Jones B, Guo YD et al. cDNA cloning of human retinoic acid-metabolizing enzyme (hP450RAI) identifies a novel family of cytochromes P450. J Biol Chem 1997 272 : 18538 41.
40. White JA, Ramshaw H, Taimi M et al. Identification of the human cytochrome P450, P450RAI-2, which is predominantly expressed in the adult cerebellum and is responsible for all-trans-retinoic acid metabolism. Proc Natl Acad Sci USA 2000 97 : 6403 8.
41. Abu-Abed S, MacLean G, Fraulob V et al. Differential expression of the retinoic acid-metabolizing enzymes CYP26A1 and CYP26B1 during murine organogenesis. Mech Dev 2002 110 : 173 7.
42. Tay YM, Tam WL, Ang YS et al. MicroRNA-134 modulates the differentiation of mouse embryonic stem cells, where it causes post-transcriptional attenuation of Nanog and LRH1. Stem Cells 2008 26 : 17 29.
43. Welch C, Chen Y, Stallings RL. MicroRNA-34a functions as a potential tumor suppressor by inducing apoptosis in neuroblastoma cells. Oncogene 2007 26 : 5017 22.
44. Garzon R, Pichiorri F, Palumbo T et al. MicroRNA gene expression during retinoic acid-induced differentiation of human acute promyelocytic leukemia. Oncogene 2007 26 : 4148 57.
45. Gruaz DC, Didierjean L, Gumowski-Sunek D et al. Effect of topical retinoic acid on the interleukin 1 alpha and beta immunoreactive pool in normal human epidermis. Br J Dermatol 1990 123 : 283 9.
46. Fisher GJ, Esmann J, Griffiths CE et al. Cellular, immunologic and biochemical characterization of topical retinoic acid-treated human skin. J Invest Dermatol 1991 96 : 699 707.